Table I.
Demographics and clinical characteristics of sample.
| EBRT (N = 47) | |||
|---|---|---|---|
| Mean (SE) | Range | n (%) | |
| Age in years | 64.50 (1.11) | 49–81 | |
| Ethnicity | |||
| Caucasian | 30 (63.8) | ||
| African-American | 11 (23.4) | ||
| Other | 6 (12.8) | ||
| Clinical T stage | |||
| T1 (a–c) | 14 (29.7) | ||
| T2 (a–c) | 26 (55.3) | ||
| T3 (a–c) | 7(15.0) | ||
| Gleason score | |||
| 6 | 5 (10.6) | ||
| 7 | 19 (40.4) | ||
| 8 | 12 (25.5) | ||
| 9 | 10 (21.3) | ||
| Others | 1 (2.1) | ||
| BMI | 29.81 (0.61) | 22.9–40.7 | |
| Total Dosage EBRT (Gray) | |||
| 66.0 | 1 (2.1) | ||
| 68.4 | 7 (14.9) | ||
| 75.6 | 39 (83.0) | ||
| PSA Levels (ng/ml) | |||
| Baseline | 7.71 (2.88) | 0.01–104.0 | |
| Completion | 0.34 (0.15) | 0.01–4.84 | |
| Albumin levels (g/dl) | 3.98 (0.07) | 2.7–4.5 | |
| Testosterone (ng/dl) | 252.32 (32.28) | 20–536 | |
| TSH (µIU/ml) | 2.01 (0.21) | 0.24–3.84 | |
| Hemoglobin (g/dl) | 13.69 (0.16) | 10.9–15.8 | |
| FACT-F score | |||
| Baseline | 43.95 (1.28) | 23–52 | |
| Midpoint (day 19–21) | 38.36 (1.52) | 16–52 | |
| Endpoint (day 38–42) | 39.48 (1.45) | 14–52 | |
| HAM-D score | |||
| Baseline | 1.16 (0.24) | 0–8 | |
| Midpoint (day 19–21) | 2.22 (0.49) | 0–13 | |
| Endpoint (day 38–42) | 1.49 (0.20) | 0–8 | |
Demographic and clinical characteristics of sample are presented as mean with standard error (SE), range, number (n) and percentage (%) of subjects.
BMI, body mass index; dl, decilitre; EBRT, external beam radiation therapy; PSA, prostate specific antigen; TSH, thyroid stimulating hormone.; FACT-F, Functional Assessment of Cancer Therapy-Fatigue; HAM-D, Hamilton Depression scale.